Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.

Marianne van Vugt,Rik de Greef,Tomoko Freshwater,Eric Mangin,Frank van Aarle,Anna Kondic

Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.

2016

Marianne van Vugt
Rik de Greef
Tomoko Freshwater
Eric Mangin
Frank van Aarle
Anna Kondic

3063Background: Monoclonal antibodies (mAb) can evoke immunogenicity, leading to production of antidrug antibodies (ADA). Pembro, a humanized mAb against PD-1, has demonstrated efficacy in NSCLC an...

Keywords:

Melanoma
non-small cell lung cancer (NSCLC)
Immunogenicity
Pathology
Pembrolizumab
Medicine
Cancer research
Antibody
in patient
advanced melanoma
Monoclonal antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations